Diversion of methadone and buprenorphine by patients in opioid substitution treatment in Sweden: Prevalence estimates and risk factors

International Journal of Drug Policy

Volumn 26, Issue 2, 2015, Pages 183-190

  Johnson, Björn ^a   Richert, Torkel ^a  

^a MALMÖ UNIVERSITY   (Sweden)

Author keywords

Buprenorphine; Diversion; Illicit use; Methadone; Opioid substitution treatment

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; ILLICIT DRUG; METHADONE; OPIATE;

ADULT; AGE DISTRIBUTION; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION DRUG DIVERSION; PREVALENCE; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR; SELF REPORT; SOCIAL ASPECT; SOCIAL INTERACTION; SOCIOECONOMICS; STRUCTURED INTERVIEW; SWEDEN; YOUNG ADULT; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA;

ADULT; BUPRENORPHINE; FEMALE; HUMANS; LOGISTIC MODELS; MALE; METHADONE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PRESCRIPTION DRUG DIVERSION; PREVALENCE; RISK FACTORS; SURVEYS AND QUESTIONNAIRES; SWEDEN; YOUNG ADULT;

EID: 84920720089     PISSN: 09553959     EISSN: 18734758     Source Type: Journal    
DOI: 10.1016/j.drugpo.2014.10.003     Document Type: Article

References (52)

1. Aalto M., Visapää J.P., Halme J.T., Fabritius C., Salaspuro M. Effectiveness of buprenorphine maintenance treatment as compared to a syringe exchange program among buprenorphine misusing opioid-dependent patients. Nordic Journal of Psychiatry 2011, 65:238-243. 10.3109/08039488.2010.531762.
2. Amato L., Minozzi S., Davoli M., Vecchi S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database of Systematic Reviews 2011, 10. 10.1002/14651858.CD004147.pub4.
3. Auriacombe M., Fatseas M., Dubernet J., Daulouede J.P., Tignol J. French field experience with buprenorphine. American Journal on Addictions 2004, 13:S17-S28.
4. Bourgois P. The moral economies of homeless heroin addicts: Confronting ethnography, HIV risk, and everyday violence in San Francisco shooting encampments. Substance Use and Misuse 1998, 33:2323-2351.
5. Bourgois P., Schonberg J. Righteous dopefiend 2009, University of California Press, Berkeley.
6. Bridge T.P., Fudala P.J., Herbert S., Leiderman D.B. Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependence. Drug and Alcohol Dependence 2003, 70:S79-S85.
7. Comer S.D., Sullivan M.A., Vosburg S.K., Manubay J., Amass L., Cooper Z.D., et al. Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers. Addiction 2010, 105:709-718. 10.1111/j.1360-0443.2009.02843.x.
8. Dale-Perera A., Goulão J., Stöver H. Quality of care provided to patients receiving opioid maintenance treatment in Europe: Results from the EQUATOR analysis. Heroin Addiction and Related Clinical Problems 2012, 14:23-38.
9. Davis W.R., Johnson B.D. Prescription, opioid use, misuse, and diversion among street drug users in New York City. Drug and Alcohol Dependence 2007, 92:267-276.
10. Duffy P., Baldwin H. The nature of methadone diversion in England: A Merseyside case study. Harm Reduction Journal 2012, 9. 10.1186/1477-7517-9-3.
11. Ebaugh H.R. Becoming an ex: The process of role exit 1988, University of Chicago Press, Chicago.
12. Elliot E., Watson A.J., Harries U. Harnessing expertise: Involving peer interviewers in qualitative research with hard-to-reach populations. Health Expectations 2002, 5:172-178.
13. Fudala P.J., Johnson R.E. Development of opioid formulations with limited diversion and abuse potential. Drug and Alcohol Dependence 2006, 83:S40-S47.
14. Fugelstad A., Johansson L.A., Thiblin I. Allt fler dör av metadon: 'Läckage' från dagens mer liberala behandlingsprogram kan vara en orsak. Läkartidningen 2010, 107:1225-1228.
15. Fugelstad A., Stenbacka M., Leifman A., Nylander M., Thiblin I. Methadone maintenance treatment: The balance between life-saving treatment and fatal poisonings. Addiction 2007, 102:406-412. 10.1111/j.1360-0443.2006.01714.x.
16. Griffiths P., Gossop M., Povis B., Strang J. Reaching hidden populations of drug users by privileged access interviewers: Methodological and practical issues. Addiction 1993, 88:1617-1626.
17. Gwin M.S., Kelly S.M., Brown B.S., Schacht Reisinger H., Peterson J.A., Ruhf A., et al. Uses of diverted methadone and buprenorphine by opioid-addicted individuals in Baltimore, Maryland. American Journal on Addictions 2009, 18:346-355.
18. Håkansson A., Medvedeo A., Andersson M., Berglund M. Buprenorphine misuse among heroin and amphetamine users in Malmö, Sweden: Purpose of misuse and route of administration. European Addiction Research 2007, 13:207-215.
19. Hall M.T., Leukefeld C.G., Havens J.R. Factors associated with high-frequency illicit methadone use among rural Appalachian drug users. American Journal of Drug and Alcohol Abuse 2013, 39:241-246.
20. Harris M., Rhodes T. Methadone diversion as a protective strategy: The harm reduction potential of 'generous constraints'. International Journal of Drug Policy 2013, 24:e43-e50.
21. Havnes I.A., Clausen T., Middleton A. 'Diversion' of methadone or buprenorphine: 'Harm' versus 'helping'. Harm Reduction Journal 2013, 10:24. 10.1186/1477-7517-10-24.
22. Johnson B. After the storm. Developments in maintenance treatment policy and practice in Sweden 1987-2006. On the margins: Nordic alcohol and drug treatment 1885-2007 2007, NAD, Helsingfors. J. Edman, K. Stenius (Eds.).
23. Johnson B., Richert T. Diversion of methadone and buprenorphine from opioid substitution treatment - A staff perspective. Journal of Psychoactive Drugs 2014, 46:427-435.
24. Kuebler D., Hausser D. The Swiss hidden population study: Practical and methodological aspects of data collection by privileged access interviewers. Addiction 1997, 92:325-334.
25. Madden M.E., Shapiro S.L. The methadone epidemic: Methadone-related deaths on the rise in Vermont. American Journal of Forensic Medicine and Pathology 2011, 32:131-135.
26. Mattick R.P., Breen C., Kimber J., Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database of Systematic Reviews 2009, 3. 10.1002/14651858.CD002209.pub2.
27. Mattick R.P., Kimber J., Breen C., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews 2008, 2. 10.1002/14651858.CD002207.pub3.
28. Mégarbane B., Hreiche R., Pirnay S., Marie N., Baud F.J. Does high-dose buprenorphine cause respiratory depression?. Toxicological Reviews 2006, 25:79-85.
29. Milroy C.M., Forrest A.R.W. Methadone deaths: A toxicological analysis. Journal of Clinical Pathology 2000, 53:277-281. 10.1136/jcp.53.4.277.
30. Moatti J.P., Vlahov D., Feroini I., Perri V., Odabia Y. Multiple access to sterile syringes for injection drug users: Vending machines, needle exchange programs and legal pharmacy sales in Marseille, France. European Addiction Research 2001, 7:40-45.
31. Monte A.A., Mandell T., Wilford B.B., Tennyson J., Boyer E.W. Diversion of buprenorphine/naloxone coformulated tablets in a region with high prescribing prevalence. Journal of Addictive Diseases 2009, 28:226-231.
32. Morgan O., Griffiths C., Hickman M. Association between availability of heroin and methadone and fatal poisoning in England and Wales 1993 to 2004. International Journal of Epidemiology 2006, 35:1579-1585. doi:10.10937ije7dyl207.
33. Obadia Y., Perrin V., Feroini I., Vlahov D., Moatti J.P. Injecting misuse of buprenorphine among French drug users. Addiction 2001, 96:267-272.
34. Otiashvili D., Zabransky T., Kirtadze I., Piralishvili G., Chavchanideze M., Miovsky M. Why do the clients of Georgien needle exchange programmes inject buprenorphine?. European Addiction Research 2010, 16:1-8.
35. Piercefield E., Archer P., Kemp P., Mallonee S. Increase in unintentional medication overdose deaths: Oklahoma, 1994-2006. American Journal of Preventive Medicine 2010, 39:357-363. 10.1016/jamepre.2010.05.016.
36. Richert T., Johnson B. Illicit use of methadone and buprenorphine among adolescents and young adults in Sweden. Harm Reduction Journal 2013, 10:27.
37. Ritter A., Di Natale R. The relationship between take-away methadone policies and methadone diversion. Drug and Alcohol Review 2005, 24:347-352.
38. Roche A., McCabe S., Smyth B.R. Illicit methadone use and abuse in young people accessing treatment for opiate dependence. European Addiction Research 2008, 14:219-225.
39. Schmidt C.S., Schulte B., Wickert C., Thane K., Kuhn S., Verthein U., et al. Non-prescribed use of substitution medication among German drug users: Prevalence, motives and availability. International Journal of Drug Policy 2013, 24:E111-E114.
40. Schuman-Olivier Z., Albanese M., Nelson S.E., Roland L., Puopolo F., Klinker L., et al. Self-treatment. Illicit buprenorphine use by opioid-dependent treatment seekers. Journal of Substance Abuse Treatment 2010, 39:41-50.
41. Seldén T., Ahlner J., Druid H., Kronstrand R. Toxicological and pathological findings in a series of buprenorphine related deaths. Possible risk factors for fatal outcome. Forensic Science International 2012, 220:284-290.
42. Seymour A., Black M., Jay J., Cooper G., Weir C., Oliver J. The role of methadone in drug-related deaths in the west of Scotland. Addiction 2003, 98:995-1002.
43. Simojoki K., Alho H. A five-year follow-up of buprenorphine abuse potential. Journal of Alcoholism & Drug Dependence 2013, 1:111. 10.4172/jaldd.1000111.
44. Simojoki K., Vorma H., Alho H. A retrospective evaluation of patients switched from buprenorphine (subutex) to the buprenorphine/naloxone combination (suboxone). Substance Abuse Treatment, Prevention, and Policy 2008, 3:16. 10.1186/1747-597X-3-16.
45. Spunt B., Hunt D.E., Lipton D.S., Goldsmith D.S. Methadone diversion: A new look. Journal of Drug Issues 1986, 16:569-583.
46. Strang J., Hall W., Hickman M., Bird S.M. Impact of supervision of methadone consumption on deaths related to methadone overdose (1993-2008): Analyses using OD4 index in England and Scotland. British Medical Journal 2010, 341. 10.1136/bmj.c4851.
47. Svensson B. Pundare, jonkare och andra [Speedfreaks, junkies and others] 1996, Carlssons, Stockholm.
48. Vlahov D., O'Driscoll P., Mehta S.H., Ompad D.C., Gern R., Galai N., et al. Risk factors for methadone outside treatment programs: Implications for HIV treatment among injection drug users. Addiction 2007, 102:771-777.
49. Wikner B.N., Öhman I., Seldén T., Druid H., Brandt L., Kieler H. Opioid-related mortality and filled prescriptions for buprenorphine and methadone. Drug and Alcohol Review 2014, 33:491-498.
50. Winstock A.R., Lea T. Diversion and injection of methadone and buprenorphine among clients in public opioid treatment clinics in New South Wales, Australia. Substance Use and Misuse 2010, 45:240-252. 10.3109/10826080903080664.
51. Winstock A.R., Lea T., Sheridan J. Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia. International Journal of Drug Policy 2008, 19:450-458. 10.1016/j.drugpo.2007.03.002.
52. Yokell M.A., Zaller N.D., Green T.C., Rich J.D. Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: An international review. Current Drug Abuse Reviews 2011, 4:28-41.